TCGA-85-6175-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 63
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.943 |
| 2 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.940 |
| 3 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.928 |
| 4 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.920 |
| 5 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.913 |
| 6 | X17a4d870.71ef.4580.91db.071219517f26 | — | cohortSQ1 | 0.911 |
| 7 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.904 |
| 8 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.904 |
| 9 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.901 |
| 10 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.690 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.580 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.490 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.490 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |